PPARD and osteoarthritis: Within tier 1, ten candidates have previously been studied in clinical trials of efficacy or in cohort studies of osteoarthritis (six arising from new signals: PPARD, NR3C1, VDR, MAPK14, IGF1R, and CHST3).